Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Working Capital Changes (2016 - 2025)

Heron Therapeutics' Other Working Capital Changes history spans 14 years, with the latest figure at -$5.4 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 188.15% year-over-year to -$5.4 million; the TTM value through Dec 2025 reached -$878000.0, down 108.84%, while the annual FY2025 figure was -$878000.0, 108.84% down from the prior year.
  • Other Working Capital Changes reached -$5.4 million in Q4 2025 per HRTX's latest filing, down from $5.2 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $8.6 million in Q1 2025 to a low of -$9.5 million in Q2 2023.
  • Average Other Working Capital Changes over 5 years is $49950.0, with a median of $25000.0 recorded in 2023.
  • The largest YoY upside for Other Working Capital Changes was 3775.68% in 2025 against a maximum downside of 3118.69% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $2.7 million in 2021, then skyrocketed by 75.19% to $4.7 million in 2022, then plummeted by 203.58% to -$4.9 million in 2023, then soared by 226.06% to $6.2 million in 2024, then crashed by 188.15% to -$5.4 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Other Working Capital Changes are -$5.4 million (Q4 2025), $5.2 million (Q3 2025), and -$9.3 million (Q2 2025).